- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05481658
Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
A Phase I, Open Label Study Employing the Topical Immunomodulator Diphencyprone to Improve Efficacy of PD-1 or PD-L1 Immune Checkpoint Inhibition in the Treatment of Advanced Cancer With Cutaneous Metastases
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Vicky K Wong, MS, CCRC
- Phone Number: 212-241-3288
- Email: vicky.wong@mssm.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Recruiting
- Icahn School of Medicine at Mount Sinai
-
Principal Investigator:
- Nicholas Gulati
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Clinically diagnosed cancer with at least three cutaneous metastasis sites that are able to be biopsied.
- Subject's oncologist plans as next standard of care treatment to use an FDA- approved PD-1 or PD-L1 ICI therapy. In other words, the subject would be treated with PD-1 or PD-L1 ICI therapy even if not taking part in this study. Subjects can be either ICI-naïve (never having received ICI previously), or may have progressed/relapsed during ICI therapy, but the treating oncologist has elected to continue PD-1 or PD-L1 ICI therapy.
- Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Women of child-bearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately:
A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
- Ability to understand and the willingness to sign a written informed consent.
Exclusion Criteria:
- Subjects may not be receiving any other investigational agents.
- Subjects must not be receiving combination ICI, such as a PD-1 inhibitor with a CTLA-4 inhibitor.
- Subjects taking any of the following systemic therapies: corticosteroids, immunosuppressants, and/or any other medications (systemic or topical) that may affect the outcome of the study in the opinion of the investigator
- Subjects with any underlying diseases or dermatological conditions of the affected areas that require the use of interfering topical or systemic therapy, or that may, in the opinion of the investigator, impair immune responses such as HIV or lymphadenectomy of the axillary lymph node basin that drains the skin where DPCP is to be applied.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to DPCP, or any of the other components of the DPCP ointment formulation.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Diphencyprone (DPCP)
0.4% and 0.04% ointment
|
topical immunomodulator
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects with a grade 3 adverse event
Time Frame: at Day 98 or 128
|
Safety and tolerability of dual-therapy DPCP plus immune checkpoint inhibition will be measured as the proportion of subjects with a grade 3 on the Common Terminology Criteria for Adverse Events (CTCAE) criteria for eczema, version 5.0.
|
at Day 98 or 128
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nicholas Gulati, MD, PhD, Icahn School of Medicine at Mount Sinai
- Principal Investigator: Philip Friedlander, MD, PhD, Icahn School of Medicine at Mount Sinai
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY-21-01421
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Investigators whose proposed use of the data has been approved by an independent review committee ('learned intermediary') identified for this purpose.
Any purpose. Specify Other Mechanism PI to be contacted
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cutaneous Metastases
-
Copenhagen University Hospital at HerlevWithdrawnUlcerated Cutaneous MetastasesDenmark
-
NanOlogy, LLCUS Biotest, Inc.Completed
-
Herlev HospitalCompleted
-
Alpha Tau Medical LTD.RecruitingSkin Cancer | Cutaneous Tumor | Cutaneous MetastasisFrance
-
University of Michigan Rogel Cancer CenterRecruitingMetastatic Melanoma | Liver Metastases | Melanoma, Mucosal | Melanoma, Ocular | Melanoma, CutaneousUnited States
-
AmgenMerck Sharp & Dohme LLCCompletedHepatocellular Carcinoma | Liver Metastases | Liver Tumors | Cutaneous or Subcutaneous Lymph NodeUnited States, Belgium, Germany, Korea, Republic of, Spain, Austria, Switzerland, Australia, Poland
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingMetastatic Melanoma | Metastatic Cutaneous Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Mucosal MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingClinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage 0 Cutaneous Melanoma AJCC v8 | Clinical Stage I Cutaneous Melanoma AJCC v8 | Clinical Stage IA Cutaneous Melanoma AJCC v8 | Clinical... and other conditionsUnited States
-
Melanoma Institute AustraliaWithdrawnMelanoma | In-Transit Metastasis of Cutaneous MelanomaAustralia
-
Jonsson Comprehensive Cancer CenterBristol-Myers Squibb; Array BioPharmaRecruitingMetastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous... and other conditionsUnited States
Clinical Trials on Diphencyprone (DPCP)
-
Nicholas GulatiActive, not recruiting
-
Rockefeller UniversityCompletedMelanoma | Neoplasm MetastasisUnited States
-
RXi Pharmaceuticals, Corp.UnknownPlantar Warts | Common Warts | HPV (Human Papillomavirus) | Periungual WartsUnited States
-
Innovaderm Research Inc.CompletedHypersensitivity, Delayed | Immunosuppression | Ultraviolet Rays | Immune Tolerance/Drug EffectsCanada
-
University of Alabama at BirminghamActive, not recruiting
-
Ain Shams UniversityCompleted
-
University of MinnesotaNational Alopecia Areata FoundationRecruiting